Form 8-K Adverum Biotechnologies, For: Nov 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Adverum Biotechnologies (ADVM) PT Lowered to $10 at RBC Capital
November 5, 2024 6:57 AM ESTRBC Capital analyst Luca Issi lowered the price target on Adverum Biotechnologies (NASDAQ: ADVM) to $10.00 (from $12.00) while maintaining a Sector Perform rating.
The analyst comments "ADVM reported 3Q24 results and updated timelines for the next LUNA readout (52-week results now anticipated... More
